Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 6.699 EUR -0.31% Market Closed
Market Cap: 187.6m EUR

Intrinsic Value

The intrinsic value of one HYL stock under the Base Case scenario is 19.907 EUR. Compared to the current market price of 6.699 EUR, Hyloris Pharmaceuticals SA is Undervalued by 66%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HYL Intrinsic Value
19.907 EUR
Undervaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Hyloris Pharmaceuticals SA

HYL
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for HYL cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Hyloris Pharmaceuticals SA
XBRU:HYL
BE
Pharmaceuticals
Market Cap
187.6m EUR
IPO
Jun 29, 2020
BE
Pharmaceuticals
Market Cap
187.6m EUR
IPO
Jun 29, 2020
Price
€false
EPS
€false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HYL?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Hyloris Pharmaceuticals SA
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Hyloris Pharmaceuticals SA

Balance Sheet Decomposition
Hyloris Pharmaceuticals SA

Current Assets 32.8m
Cash & Short-Term Investments 28m
Receivables 4.4m
Other Current Assets 454k
Non-Current Assets 12.7m
Long-Term Investments 4.8m
PP&E 2.1m
Intangibles 3.8m
Other Non-Current Assets 2m
Efficiency

Free Cash Flow Analysis
Hyloris Pharmaceuticals SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Hyloris Pharmaceuticals SA

Revenue
5.1m EUR
Cost of Revenue
-155k EUR
Gross Profit
4.9m EUR
Operating Expenses
-17.7m EUR
Operating Income
-12.8m EUR
Other Expenses
531k EUR
Net Income
-12.2m EUR
Fundamental Scores

HYL Profitability Score
Profitability Due Diligence

Hyloris Pharmaceuticals SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
36/100
Profitability
Score

Hyloris Pharmaceuticals SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

HYL Solvency Score
Solvency Due Diligence

Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
87/100
Solvency
Score

Hyloris Pharmaceuticals SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HYL Price Targets Summary
Hyloris Pharmaceuticals SA

Wall Street analysts forecast HYL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HYL is 13.94 EUR with a low forecast of 5.05 EUR and a high forecast of 21 EUR.

Lowest
Price Target
5.05 EUR
25% Downside
Average
Price Target
13.94 EUR
108% Upside
Highest
Price Target
21 EUR
213% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Hyloris Pharmaceuticals SA
does not pay dividends
Shareholder Yield

Current shareholder yield for HYL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HYL Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one HYL stock?

The intrinsic value of one HYL stock under the Base Case scenario is 19.907 EUR.

Is HYL stock undervalued or overvalued?

Compared to the current market price of 6.699 EUR, Hyloris Pharmaceuticals SA is Undervalued by 66%.

Back to Top